Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis

American Journal of Health-System Pharmacy

Volumn 57, Issue 18, 2000, Pages 1685-1697

  Lindley, C ^a   Blower, P ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anti emetics; Antineoplastic agents; Dolasetron; Drug administration routes; Granisetron; Nausea; Ondansetron; Serotonin antagonists; Toxicity; Vomiting

Indexed keywords

CHLORMETHINE; CISPLATIN; CYCLOHEXIMIDE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DIACETOXYSCIRPENOL; DOLASETRON MESILATE; DOXORUBICIN; EMETINE; GRANISETRON; IPECAC; ONDANSETRON; PEPTIDE YY; PHENYLBIGUANIDE; PYROGALLOL; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; STAPHYLOCOCCUS ENTEROTOXIN B; TRIMELAMOL;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; ENTEROCHROMAFFIN CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE; VOMITING;

EID: 0034666393     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.18.1685     Document Type: Review

References (119)

1. Effect of ablation of medullary emetic chemoreceptor trigger zone on vomiting responses to cerebral intraventricular injection of adrenaline, apomorphine, and pilocarpine in the cat
2. Physiology and pharmacology of vomiting
3. Discrete lesions of the area postrema abolish radiation-induced emesis in the dog
4. Relief of intractable vomiting from surgical lesions in the area postrema
5. Locus of emetic action following irradiation
6. The abdominal visceral innervation and the emetic reflex: Pathways, pharmacology, and plasticity
7. Comparative aspects of the area postrema: Fine structural considerations help to determine its function
8. 3 receptors in mammalian hindbrain
9. Neuropharmacology of emesis induced by anti-cancer therapy
10. The mechanism of emesis induced by anti-cancer therapies
11. The physiology of emesis induced by anti-cancer therapy
12. Emesis research: A concise history of the critical concepts and experiments
13. The pharmacology of 5-HT release from enterochromaffin cells
14. The role of free radicals and nitric oxide in the induction of emesis
15. The effects of x-irradiation on the sensitivity of guinea-pig isolated ileum to 5-hydroxytryptamine and acetylcholine-mediated responses
16. Pyrogallol, a generator of free radicals, is emetogenic in Suncus murinus
17. 3 receptor antagonists?
18. Further studies of the antiemetic activity of granisetron against whole body x-irradiation or cisplatin-induced emesis in the ferret
19. 3 receptors
20. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine
21. Radiotherapy-induced emesis
22. 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists
23. 3 receptors mediate cisplatin-induced emesis in dogs
24. Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients
25. Neurotransmitters and receptors in the emetic pathway
26. Vagal mechanisms controlling serotonin release from the gastrointestinal tract and pyloric motor function
27. How do toxic emetic stimuli cause 5-HT release in the gut and brain?
28. 3 antagonists injected into the area postrema inhibit cisplatin induced emesis in the ferret
29. Pharmacology and preclinical antiemetic properties of ondansetron
30. 3-receptor antagonists and emesis: A preclinical review
31. The concept of selectivity in 5-HT receptor research
32. 3 binding sites in rat brain cortical membranes
33. 3 receptor antagonism in the control of cytostatic-induced emesis
34. Characterization of the muscarine receptors involved in the modulation of serotonin release from the vascularly perfused small intestine of guinea pig
35. Cholinergic modulation of the release of 5-hydroxytryptamine from the guinea pig ileum
36. Ligand-gated ion channels opened by 5-HT in molluscan neurons
37. Effects of anticancer drugs on enzyme activities and serotonin release from ileal tissue in ferrets
38. Granisetron, a 5-HT3-receptor antagonist, inhibited cisplatin-induced 5-hydroxytryptamine release in the isolated ileum of ferrets
39. 4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine
40. Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents
41. Granisetron: The second serotonin-receptor antagonist
42. Ondansetron clinical pharmacokinetics
43. Antagonism of the effects of 5-hydroxytryptamine on the rabbit isolated vagus nerve by BRL 43694 and metoclopramide
44. 3 receptors
45. 3 receptors mediate cisplatin-induced emesis in dogs
46. 3 antagonist
47. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare
48. Effect of GR38032F on cisplatin-induced and cyclophosphamide-induced emesis in the ferret
49. Phase I and other dose-ranging studies of ondansetron
50. Ondansetron metabolism and pharmacokinetics
51. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers
52. The clinical approach to chemotherapy-induced emesis
53. The piglet as a suitable animal model for studying the delayed phase of chemotherapy-induced emesis
54. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons
55. Volatile general anaesthetic actions on recombinant nACh-α-7,5-HT3, and chimeric nACh-α-7-5-HT3 receptors expressed in Xenopus oocytes
56. 3 receptor-channels on NCB-20 neuroblastoma cells by favoring and stabilizing the open channel state
57. Interaction of oestrone and 17 beta-oestradiol with the 5-HT3 receptor
58. Neuronal 5-HT receptors in the periphery
59. 3 antagonist
60. Oral granisetron to prevent chemotherapy-induced nausea and vomiting: Cost and efficacy
61. Adoption of an all oral antiemetic regimen for prevention of acute chemotherapy-induced emesis (CIE): Assessment of clinical and economic outcomes
62. Proposal for classifying the acute emetogenicity of cancer chemotherapy
63. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study
64. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy
65. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy
66. Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis
67. Efficacy of two oral dose regimens of granisetron
68. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy
69. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study
70. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy
71. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis
72. Oral ondansetron (GR 38032F) for the control of acute and delayed cyclophosphamide-induced emesis
73. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient
74. Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy
75. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis: A Phase II trial in women
76. Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
77. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy
78. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: A multicentre, double-blind, double-dummy, randomised, parallel-group study
79. Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients
80. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy
81. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy
82. Therapeutic equivalence of single oral doses of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy
83. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone
84. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: Efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy
85. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron
86. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials
87. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
88. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy
89. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy-induced emesis: A randomized, single-blind, multicenter study
90. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy
91. Effect of schedule and maintenance on the anti-emetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A Phase III trial by the National Cancer Institute of Canada Clinical Trials Group
92. Ondansetron in the treatment of nausea and vomiting induced by chemotherapy
93. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin-based chemotherapy
94. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer
95. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
96. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis induction by moderately to highly emetogenic chemotherapy: Dose, schedule, and route of administration
97. NCCN antiemesis practice guidelines
98. Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients
99. Prognostic factors influencing cisplatin-induced emesis
100. Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion
101. Methodology of antiemetic trials: A review
102. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
103. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy
104. A randomized, double-blind comparison of IV ondansetron alone and in combination with IV dexamethasone in the prevention of high-dose cisplatin-induced emesis
105. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients
106. Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy
107. Prevention of cisplatin-induced emesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone
108. Does dexamethasone enhance control of acute cisplatin-induced emesis by ondansetron?
109. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis
110. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis
111. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer